CANbridge pays $30mm up front for rights to Puma's Nerlynx; Agreement Terminated
Puma Biotechnology Inc. granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its breast cancer therapy Nerlynx (nerlatinib) in mainland China, Taiwan, Hong Kong, and Macau.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com